Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype.

作者: Melissa K. McConechy , Anniina Färkkilä , Hugo M. Horlings , Aline Talhouk , Leila Unkila-Kallio

DOI: 10.1093/JNCI/DJW134

关键词:

摘要: The histopathologic features of adult granulosa cell tumors (AGCTs) are relatively nonspecific, resulting in misdiagnosis other cancers as AGCT, a problem that has not been well characterized. FOXL2 mutation testing was used to stratify 336 AGCTs from three European centers into categories: 1) mutant molecularly defined AGCT (MD-AGCT) (n = 256 336), 2) wild-type (n = 17 3) misdiagnosed tumor types (n = 63 336). All statistical tests were two-sided. overall and disease-specific survival the cases lower than MD-AGCTs (P < .001). accounted for 71.9% deaths within five years. In population-based cohort, MD-AGCT patients different age-matched, controls. Even though 35.2% all our study experienced relapse, is usually an indolent disease. historical, premolecular data underpinning clinical understanding likely skewed by inclusion cases, future management strategies should reflect potential surgical cure long even after relapse.

参考文章(27)
Terry M. Therneau, Patricia M. Grambsch, Modeling Survival Data: Extending the Cox Model ,(2000)
Stacey Jamieson, Ralf Butzow, Noora Andersson, Maria Alexiadis, Leila Unkila-Kallio, Markku Heikinheimo, Peter J Fuller, Mikko Anttonen, The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary Modern Pathology. ,vol. 23, pp. 1477- 1485 ,(2010) , 10.1038/MODPATHOL.2010.145
Hannah S. van Meurs, Ewoud Schuit, Hugo M. Horlings, Jacobus van der Velden, Willemien J. van Driel, Ben Willem J. Mol, Gemma G. Kenter, Marrije R. Buist, Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary. Gynecologic Oncology. ,vol. 134, pp. 498- 504 ,(2014) , 10.1016/J.YGYNO.2014.06.021
Colin J.R. Stewart, Maria Alexiadis, Maxine L. Crook, Peter J. Fuller, An immunohistochemical and molecular analysis of problematic and unclassified ovarian sex cord-stromal tumors. Human Pathology. ,vol. 44, pp. 2774- 2781 ,(2013) , 10.1016/J.HUMPATH.2013.07.028
Stefan Kommoss, Michael S Anglesio, Robertson Mackenzie, Winnie Yang, Janine Senz, Julie Ho, Lynda Bell, Sylvia Lee, Julie Lorette, David G Huntsman, C Blake Gilks, FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines Modern Pathology. ,vol. 26, pp. 860- 867 ,(2013) , 10.1038/MODPATHOL.2012.226
Kasmintan A. Schrader, Bella Gorbatcheva, Janine Senz, Alireza Heravi-Moussavi, Nataliya Melnyk, Clara Salamanca, Sarah Maines-Bandiera, Susanna L. Cooke, Peter Leung, James D. Brenton, C. Blake Gilks, John Monahan, David G. Huntsman, The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors PLoS ONE. ,vol. 4, pp. e7988- ,(2009) , 10.1371/JOURNAL.PONE.0007988
Nadeem R. Abu-Rustum, Antonella Restivo, Joseph Ivy, Robert Soslow, Paul Sabbatini, Yukio Sonoda, Richard R. Barakat, Dennis S. Chi, Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary Gynecologic Oncology. ,vol. 103, pp. 31- 34 ,(2006) , 10.1016/J.YGYNO.2006.01.050
Rotem Gershon, Sarit Aviel-Ronen, Jacob Korach, Vered Daniel-Carmi, Camila Avivi, Dalia Bar-Ilan, Iris Barshack, Dror Meirow, Gilad Ben-Baruch, Yoram Cohen, FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. Gynecologic Oncology. ,vol. 122, pp. 580- 584 ,(2011) , 10.1016/J.YGYNO.2011.05.008
Brigitte E. Miller, Beth A. Barron, Jim Y. Wan, James E. Delmore, Elvio G. Silva, David M. Gershenson, Prognostic factors in adult granulosa cell tumor of the ovary Cancer. ,vol. 79, pp. 1951- 1955 ,(1997) , 10.1002/(SICI)1097-0142(19970515)79:10<1951::AID-CNCR16>3.0.CO;2-U
Ritu Salani, Floor J. Backes, Michael Fung Kee Fung, Christine H. Holschneider, Lynn P. Parker, Robert E. Bristow, Barbara A. Goff, Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations American Journal of Obstetrics and Gynecology. ,vol. 204, pp. 466- 478 ,(2011) , 10.1016/J.AJOG.2011.03.008